Coral Laboratories Ltd

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, signalling a pause in its previously positive growth trajectory. While key profitability metrics have improved notably, revenue growth has contracted, and return on capital employed has hit a new low, raising questions about the sustainability of recent gains.

Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer with a market capitalisation of ₹174.00 crores, reported a mixed performance for Q4 FY26 ended March 2026. The company posted a net profit of ₹5.22 crores, representing a robust sequential growth of 87.77% from Q3 FY26's ₹2.78 crores, though the year-on-year comparison showed an 84.45% surge from Q4 FY25's ₹2.83 crores. However, this profit expansion came against a backdrop of declining revenues, with net sales falling 5.87% year-on-year to ₹26.48 crores from ₹28.13 crores in the corresponding quarter last year.

Coral Laboratories Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, shifting from a previously negative trend to positive growth in key profitability metrics despite a decline in net sales. This shift has prompted an upgrade in the company’s mojo grade from Strong Sell to Sell, reflecting cautious optimism amid ongoing challenges in revenue generation.

Coral Laboratories Ltd is currently rated 'Sell' by MarketsMOJO, a rating that was last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 4 May 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical micro-cap’s Mojo Score improved to 31.0, reflecting a nuanced change in market sentiment amid persistent operational headwinds.

Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 27 Apr 2026. This revision reflects deteriorating technical indicators, poor financial performance, and subdued valuation metrics, signalling heightened risk for investors amid ongoing market challenges.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 17 Apr 2026, reflecting a nuanced assessment across quality, valuation, financial trends, and technical parameters. Despite ongoing challenges in profitability and sales growth, the company’s valuation and debt profile have improved sufficiently to warrant a less severe rating, though caution remains warranted given recent performance.

Coral Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 April 2026, providing investors with the most recent and relevant data to assess the stock’s outlook.

Coral Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Coral Laboratories Ltd’s share price reached a fresh 52-week low of Rs.374.95 on 27 March 2026, marking a significant downturn amid a sustained period of negative returns and underperformance relative to its sector and broader market indices.

Coral Laboratories Ltd’s stock price declined to a fresh 52-week low of Rs.378.6 on 25 Mar 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent challenges in financial performance and market sentiment.

For the third consecutive session, Coral Laboratories Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 387.8 on 24 Mar 2026. This marks a significant drop of 7.64% over the last three days, underscoring persistent selling pressure despite an intraday high of Rs 417 earlier today.

Coral Laboratories Ltd’s share price declined to a fresh 52-week low of Rs.404.95 on 23 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low comes amid a broader market weakness and persistent challenges reflected in the company’s financial performance and valuation metrics.

Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 16 March 2026. This revision reflects deteriorating technical indicators, disappointing financial trends, and persistent valuation concerns, signalling heightened caution for investors amid ongoing underperformance relative to the broader market.

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 March 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid persistent operational headwinds and valuation considerations.